April 28, 2025 02:43 PM EDTUpdated 03:40 PM
Pharma
FDA+
Coronavirus

Vaxart says it can re­sume next-gen Covid work, will screen par­tic­i­pants for oral vac­cine tri­al

Nicole DeFeudis

Editor

Vaxart said a stop-work or­der has been lift­ed on its next-gen­er­a­tion Covid-19 vac­cine ef­forts planned un­der a Biden-era ini­tia­tive, al­low­ing it to screen par­tic­i­pants for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Ex­clu­sive: Can AI re­place an­i­mal test­ing? A new biotech launch­es to find out

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times